Aromatase inhibitors -where are we now?
1996
Aromatase Inhibitors: Current Status
Editorial
Author Information
Author(s): WR Miller
Primary Institution: ICRF Medical Oncology Unit, University Department of Clinical Oncology, Western General Hospital
Conclusion
New aromatase inhibitors show promise in treating breast cancer with fewer side effects compared to older treatments.
Supporting Evidence
- New aromatase inhibitors like Arimidex and letrozole can significantly reduce estrogen levels in patients.
- Formestane has shown a 33% objective response rate in advanced breast cancer.
- Fadrozole produced a 17% objective response rate in recurrent breast cancer after tamoxifen failure.
Takeaway
Aromatase inhibitors are drugs that help treat breast cancer by blocking the production of estrogen, which some tumors need to grow.
Limitations
The duration of treatment in most patients is still extremely limited.
Want to read the original?
Access the complete publication on the publisher's website